clinical trial · NCT05855200
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline·phase3·recruiting·n = 892
Colonic NeoplasmsNeoplasms, ColonDostarlimabCAPEOXFOLFOX
brief summary
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
started
Aug 1, 2023
primary completion
Mar 19, 2029
completion
Mar 27, 2031
last updated
Jan 23, 2026
official title
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol